310 related articles for article (PubMed ID: 28904126)
1. NLRP3 and Potassium Efflux Drive Rapid IL-1β Release from Primary Human Monocytes during
Gov L; Schneider CA; Lima TS; Pandori W; Lodoen MB
J Immunol; 2017 Oct; 199(8):2855-2864. PubMed ID: 28904126
[TBL] [Abstract][Full Text] [Related]
2. Evasion of Human Neutrophil-Mediated Host Defense during
Lima TS; Gov L; Lodoen MB
mBio; 2018 Feb; 9(1):. PubMed ID: 29440572
[TBL] [Abstract][Full Text] [Related]
3. Toxoplasma gondii activates a Syk-CARD9-NF-κB signaling axis and gasdermin D-independent release of IL-1β during infection of primary human monocytes.
Pandori WJ; Lima TS; Mallya S; Kao TH; Gov L; Lodoen MB
PLoS Pathog; 2019 Aug; 15(8):e1007923. PubMed ID: 31449558
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic outcome of islet transplantation by suppressing IL-1β and islet cellular death.
Matsuoka T; Yoshimatsu G; Sakata N; Kawakami R; Tanaka T; Yamada T; Yoshida Y; Hasegawa S; Kodama S
Sci Rep; 2020 Oct; 10(1):17920. PubMed ID: 33087823
[TBL] [Abstract][Full Text] [Related]
5. Role for Caspase-8 in the Release of IL-1β and Active Caspase-1 from Viable Human Monocytes during Toxoplasma gondii Infection.
Pandori WJ; Matsuno SY; Shin JH; Kim SC; Kao TH; Mallya S; Batarseh SN; Lodoen MB
J Immunol; 2024 Apr; 212(7):1161-1171. PubMed ID: 38372637
[TBL] [Abstract][Full Text] [Related]
6. MCC950 blocks enhanced interleukin-1β production in patients with NLRP3 low penetrance variants.
Schuh E; Groß CJ; Wagner D; Schlüter M; Groß O; Kümpfel T
Clin Immunol; 2019 Jun; 203():45-52. PubMed ID: 30974290
[TBL] [Abstract][Full Text] [Related]
7. The NLRP3 inflammasome modulates glycolysis by increasing PFKFB3 in an IL-1β-dependent manner in macrophages.
Finucane OM; Sugrue J; Rubio-Araiz A; Guillot-Sestier MV; Lynch MA
Sci Rep; 2019 Mar; 9(1):4034. PubMed ID: 30858427
[TBL] [Abstract][Full Text] [Related]
8. Dual role for inflammasome sensors NLRP1 and NLRP3 in murine resistance to Toxoplasma gondii.
Gorfu G; Cirelli KM; Melo MB; Mayer-Barber K; Crown D; Koller BH; Masters S; Sher A; Leppla SH; Moayeri M; Saeij JP; Grigg ME
mBio; 2014 Feb; 5(1):. PubMed ID: 24549849
[TBL] [Abstract][Full Text] [Related]
9. NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice-Brief Report.
van der Heijden T; Kritikou E; Venema W; van Duijn J; van Santbrink PJ; Slütter B; Foks AC; Bot I; Kuiper J
Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1457-1461. PubMed ID: 28596375
[TBL] [Abstract][Full Text] [Related]
10. Human innate immunity to Toxoplasma gondii is mediated by host caspase-1 and ASC and parasite GRA15.
Gov L; Karimzadeh A; Ueno N; Lodoen MB
mBio; 2013 Jul; 4(4):. PubMed ID: 23839215
[TBL] [Abstract][Full Text] [Related]
11. Activation of the NLRP3 Inflammasome Is Associated with Valosin-Containing Protein Myopathy.
Nalbandian A; Khan AA; Srivastava R; Llewellyn KJ; Tan B; Shukr N; Fazli Y; Kimonis VE; BenMohamed L
Inflammation; 2017 Feb; 40(1):21-41. PubMed ID: 27730320
[TBL] [Abstract][Full Text] [Related]
12. P2X7 receptor mediates NLRP3-dependent IL-1β secretion and parasite proliferation in Toxoplasma gondii-infected human small intestinal epithelial cells.
Quan JH; Huang R; Wang Z; Huang S; Choi IW; Zhou Y; Lee YH; Chu JQ
Parasit Vectors; 2018 Jan; 11(1):1. PubMed ID: 29291748
[TBL] [Abstract][Full Text] [Related]
13. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
[TBL] [Abstract][Full Text] [Related]
14. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction.
Gao R; Shi H; Chang S; Gao Y; Li X; Lv C; Yang H; Xiang H; Yang J; Xu L; Tang Y
Int Immunopharmacol; 2019 Sep; 74():105575. PubMed ID: 31299609
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Pharmacology of the NLRP3 Inflammasome Inhibitor CP-456,773 (CRID3) in Murine Models of Dermal and Pulmonary Inflammation.
Primiano MJ; Lefker BA; Bowman MR; Bree AG; Hubeau C; Bonin PD; Mangan M; Dower K; Monks BG; Cushing L; Wang S; Guzova J; Jiao A; Lin LL; Latz E; Hepworth D; Hall JP
J Immunol; 2016 Sep; 197(6):2421-33. PubMed ID: 27521339
[TBL] [Abstract][Full Text] [Related]
16. Secretion of IL-1β From Monocytes in Gout Is Redox Independent.
Alberts BM; Bruce C; Basnayake K; Ghezzi P; Davies KA; Mullen LM
Front Immunol; 2019; 10():70. PubMed ID: 30761138
[TBL] [Abstract][Full Text] [Related]
17. Priming Is Dispensable for NLRP3 Inflammasome Activation in Human Monocytes
Gritsenko A; Yu S; Martin-Sanchez F; Diaz-Del-Olmo I; Nichols EM; Davis DM; Brough D; Lopez-Castejon G
Front Immunol; 2020; 11():565924. PubMed ID: 33101286
[TBL] [Abstract][Full Text] [Related]
18. The effects of NLRP3 inflammasome inhibition by MCC950 on LPS-induced pancreatic adenocarcinoma inflammation.
Yaw ACK; Chan EWL; Yap JKY; Mai CW
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2219-2229. PubMed ID: 32507974
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting the NLRP3 inflammasome with MCC950 ameliorates retinal neovascularization and leakage by reversing the IL-1β/IL-18 activation pattern in an oxygen-induced ischemic retinopathy mouse model.
Sui A; Chen X; Shen J; Demetriades AM; Yao Y; Yao Y; Zhu Y; Shen X; Xie B
Cell Death Dis; 2020 Oct; 11(10):901. PubMed ID: 33093455
[TBL] [Abstract][Full Text] [Related]
20. Target of MCC950 in Inhibition of NLRP3 Inflammasome Activation: a Literature Review.
Wu D; Chen Y; Sun Y; Gao Q; Li H; Yang Z; Wang Y; Jiang X; Yu B
Inflammation; 2020 Feb; 43(1):17-23. PubMed ID: 31646445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
